MX2016016414A - Uso de serelaxina para reducir gdf-15. - Google Patents

Uso de serelaxina para reducir gdf-15.

Info

Publication number
MX2016016414A
MX2016016414A MX2016016414A MX2016016414A MX2016016414A MX 2016016414 A MX2016016414 A MX 2016016414A MX 2016016414 A MX2016016414 A MX 2016016414A MX 2016016414 A MX2016016414 A MX 2016016414A MX 2016016414 A MX2016016414 A MX 2016016414A
Authority
MX
Mexico
Prior art keywords
gdf
serelaxin
levels
patients
pulmonary
Prior art date
Application number
MX2016016414A
Other languages
English (en)
Spanish (es)
Inventor
Forney Prescott Margaret
Zhang Yiming
DAHLKE Marion
Severin Thomas
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2016016414A publication Critical patent/MX2016016414A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
MX2016016414A 2014-06-13 2015-06-10 Uso de serelaxina para reducir gdf-15. MX2016016414A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462011744P 2014-06-13 2014-06-13
PCT/IB2015/054399 WO2015189790A1 (en) 2014-06-13 2015-06-10 Use of serelaxin to reduce gdf-15

Publications (1)

Publication Number Publication Date
MX2016016414A true MX2016016414A (es) 2017-04-10

Family

ID=53476944

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016414A MX2016016414A (es) 2014-06-13 2015-06-10 Uso de serelaxina para reducir gdf-15.

Country Status (11)

Country Link
US (2) US20170100460A1 (cg-RX-API-DMAC10.html)
EP (1) EP3154559B1 (cg-RX-API-DMAC10.html)
JP (1) JP6820748B2 (cg-RX-API-DMAC10.html)
KR (1) KR20170018829A (cg-RX-API-DMAC10.html)
CN (1) CN106413740A (cg-RX-API-DMAC10.html)
AU (2) AU2015273097A1 (cg-RX-API-DMAC10.html)
BR (1) BR112016028833A2 (cg-RX-API-DMAC10.html)
CA (1) CA2952061A1 (cg-RX-API-DMAC10.html)
MX (1) MX2016016414A (cg-RX-API-DMAC10.html)
RU (1) RU2016147122A (cg-RX-API-DMAC10.html)
WO (1) WO2015189790A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1225742A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
CN120919282A (zh) 2013-11-21 2025-11-11 布里格姆及妇女医院股份有限公司 用于治疗肺高压的组合物和方法
CN106794233B (zh) * 2014-08-01 2021-11-12 布里格姆及妇女医院股份有限公司 与肺动脉高压的治疗有关的组合物和方法
WO2017024171A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
LT3628049T (lt) 2017-05-04 2023-08-25 Acceleron Pharma Inc. Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai
EP3988031A4 (en) * 2019-06-20 2022-08-10 Sony Group Corporation Information processing device, information processing method, and program

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101245877B1 (ko) * 2006-08-04 2013-03-20 메디치니쉐 호흐슐레 하노버 Ｇｄｆ-15 를 바탕으로 한, 심장 중재의 위험도를 평가하는수단 및 방법
ES2379104T3 (es) * 2007-05-24 2012-04-20 F. Hoffmann-La Roche Ag Métodos para evaluar el fallo cardíaco en pacientes con fibrilación auricular utilizando péptidos GDF-15
US8415301B2 (en) * 2008-05-16 2013-04-09 Corthera, Inc. Method of treating dyspnea associated with acute heart failure by administering H2 relaxin
AU2012280474A1 (en) * 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof

Also Published As

Publication number Publication date
JP2017519008A (ja) 2017-07-13
BR112016028833A2 (pt) 2017-08-22
CN106413740A (zh) 2017-02-15
CA2952061A1 (en) 2015-12-17
KR20170018829A (ko) 2017-02-20
JP6820748B2 (ja) 2021-01-27
AU2018202289A1 (en) 2018-04-26
RU2016147122A (ru) 2018-07-16
US20190022189A1 (en) 2019-01-24
RU2016147122A3 (cg-RX-API-DMAC10.html) 2019-01-28
EP3154559B1 (en) 2021-09-01
AU2015273097A1 (en) 2016-11-17
WO2015189790A1 (en) 2015-12-17
EP3154559A1 (en) 2017-04-19
US20170100460A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
Wright et al. Models to study airway smooth muscle contraction in vivo, ex vivo and in vitro: implications in understanding asthma
SA517390218B1 (ar) جهاز وطرق لتحديد النسيج التالف باستخدام قياسات الرطوبة تحت الجلد
CR20150358A (es) Derivados de exendina-4 fucionalizada
TWD170986S (zh) 活動量計
EA201500934A1 (ru) Кардио- и нефропротективная противодиабетическая терапия
EP3517544C0 (en) INSULIN ANALOGUE HAVING REDUCED BINDING STRENGTH TO INSULIN RECEPTOR AND USE THEREOF
IL245483A0 (en) Compounds to fibroblast growth factor receptor-3 (fgfr3) and therapeutic uses
JOP20130346B1 (ar) تركيبة للاستخدام في علاج زيادة الوزن والسمنة في المرضى الذين يعانون من مخاطر هالية في القلب والأوعية الدموية
SI3355919T1 (sl) Kombinacijska terapija z uporabo zaviralcev človeškega rastnega in diferenciacijskega faktorja 15 (GDF-15) in blokatorji imunskih kontrolnih točk
MX2020003049A (es) Semaglutida en la terapia medica.
EP3585260C0 (en) SENSOR CONFIGURATION IN A MEDICAL MAGNETOMETER
MX2017009294A (es) Tratamiento de pacientes pediatricos con diabetes mellitus de tipo 2 con lixisenatida.
BR112016028833A2 (pt) uso de serelaxinaa para reduzir gdf-15
DE102014222955A8 (de) Einrichtung zur Diagnostik von Durchblutungsstörungen und sich ausbildender Entzündungen bei Füßen von Patienten mit Diabetes
IN2014DN05784A (cg-RX-API-DMAC10.html)
NZ759287A (en) Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose
TN2015000315A1 (en) Methods of treating cardiovascular indications
DK3914247T3 (da) Anvendelse af migalostat til reducering af risikoen for cerebrovaskulær hændelse hos patienter med fabrys sygdom
WO2014187964A3 (en) Novel treatment of metabolic diseases
EA201690574A1 (ru) Применение пидотимода в лечении заболеваний, связанных с воспалением
Jones et al. Factors contributing to orthopaedic implant wear
IT201700025190A1 (it) Metodo in vitro e kit per predire l’andamento clinico e la sensibilita’ ai farmaci nei pazienti con nefropatia membranosa
WO2014122638A3 (en) Thalidomide and thalidomide analogues for the stimulation of stem cell factor
TWD176611S (zh) 身高體重計
UA110302C2 (en) Method of diagnosis of allergic rhinitis, combined with bronchial asthma in children